Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis
Sign Up to like & getrecommendations! Published in 2017 at "Neurology and Therapy"
DOI: 10.1007/s40120-016-0062-4
Abstract: AbstractIntroductionIn a phase 2 trial of natalizumab in Japanese patients with relapsing-remitting multiple sclerosis (RRMS), treatment-related changes in relapses, brain lesions, and disability worsening were found to be comparable with those observed in the phase… read more here.
Keywords: status; lesion free; subanalysis; lesion ... See more keywords